Dr. Patrick M. Travis, M.D.
General Practice (General Practice Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,428
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of Arkansas College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
General Practice Physician primary
AR license C-7982
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy Hospital Northwest Arkansas Rogers, AR
- Washington Regional Medical Center Fayetteville, AR
- Baxter Health Mountain Home, AR
Medical groups
- Highlands Oncology Group PA (84 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,428
- Services billed
- 300,404
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 36,210 | 62 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 30,720 | 27 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 25,200 | 175 |
| Injection, gadoterate meglumine, 0.1 ml | 24,479 | 92 |
| Injection, nivolumab, 1 mg | 22,800 | 35 |
| Injection, testosterone cypionate, 1 mg | 19,150 | 24 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 16,380 | 27 |
| Injection, pembrolizumab, 1 mg | 10,800 | 35 |
| Injection, denosumab, 1 mg | 9,000 | 57 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 7,970 | 55 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Springdale, AR | 279 |
| Prednisone Other prescribers in Springdale, AR | 175 |
| Dexamethasone Other prescribers in Springdale, AR | 172 |
| Ondansetron Odt (ondansetron) Other prescribers in Springdale, AR | 154 |
| Potassium Chloride Other prescribers in Springdale, AR | 149 |
| Omeprazole Other prescribers in Springdale, AR | 140 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Springdale, AR | 128 |
| Gabapentin Other prescribers in Springdale, AR | 114 |
| Warfarin Sodium Other prescribers in Springdale, AR | 102 |
| Revlimid (lenalidomide) | 90 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 49 payments worth $812 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $201 |
|---|---|
| Janssen Biotech, Inc. | $80.06 |
| Sun Pharmaceutical Industries Inc. | $63.32 |
| Beone Medicines USA, Inc. | $53.19 |
| Adc Therapeutics America, Inc. | $38.20 |
| Celgene Corporation | $29.88 |
| Iovance Biotherapeutics, Inc. | $28.27 |
| Jazz Pharmaceuticals Inc. | $27.85 |
| Food and Beverage | $796 |
|---|---|
| Education | $15.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Aug 4, 2025 | Education in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $178,111 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Recruiting · NCT05650632 - Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy
Genentech, Inc. - A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceuticals U.S.A., Inc. · Terminated · NCT03215030 - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.